Skip to content

5-MeO-DMT: all studies

Page 63 of 110: studies 621 to 630 of 1,097, newest first. Back to the 5-MeO-DMT overview

Research

The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness

Psychoactives February 26, 2024 Frankie A. Colosimo, Philip Borsellino, Reese I. Krider et al. 8 citations

The human brain is an extraordinarily complex organ responsible for all aspects of cognition and control. Billions of neurons form connections with thousands of other neurons, resulting in trillions of synapses that create a vast and intricate network. This network is subjected to continuous remodeling that adapts to environmental and developmental changes. The resulting neuroplasticity is...

Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.

AJNR. American journal of neuroradiology February 15, 2024 Paloma C Frautschi, Ajay P Singh, Nicholas A Stowe et al. 5 citations

The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and substance use disorders, remain unknown. Psychedelic compounds, such as psilocybin, lysergic acid diethylamide, and N,N-dimethyltryptamine, have emerged as potential therapies for these disorders because of their hypothesized ability to induce...

DOI: 10.3174/ajnr.a8118 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Brain research Therapeutic medicine

Effects of DMT on mental health outcomes in healthy volunteers

Scientific Reports February 7, 2024 Christopher Timmermann, Richard J. Zeifman, David Erritzøe et al. 37 citations

Abstract Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. The relatively lengthy duration of oral psilocybin’s acute effects (4–6 h) may have pragmatic and cost-effectiveness limitations. Here, we explored the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT), a closely related, but faster-acting...

DOI: 10.1038/s41598-024-53363-y (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment DMT Research Clinical trials +1

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology February 2, 2024 Joachim Neumann, Stefan Dhein, Uwe Kirchhefer et al. 12 citations

Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT 2A -serotonin receptors in the brain. However, a close study reveals that they also act on the heart, possibly increasing the force of contraction and beating rate and may lead to arrhythmias. Here, we will review...

Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.

Phytochemistry February 1, 2024 Rubi Barman, Pranjit Kumar Bora, Jadumoni Saikia et al. 9 citations

The family Myristicaceae harbour mind-altering phenylpropanoids like myristicin, elemicin, safrole, tryptamine derivatives such as N,N-dimethyltryptamine (DMT) and 5-methoxy N,N-dimethyltryptamine (5-MeO-DMT) and β-carbolines such as 1-methyl-6-methoxy-dihydro-β-carboline and 2-methyl-6-methoxy-1,2,3,4-tetrahydro-β-carboline. This study aimed to systematically review and propose the...

DOI: 10.1016/j.phytochem.2023.113928 (opens in new tab) Full text (opens in new tab) Myristicaceae Phenylpropanoids Tryptamine Β-carboline +7

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging February 1, 2024 Friederike Holze, Nirmal Singh, Matthias E. Liechti et al. 50 citations

Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s)...

Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways

Ageing Research Reviews February 1, 2024 Jitendra Kumar Sinha, Anchal Trisal, Shampa Ghosh et al. 29 citations

Psychedelics have traditionally been used for spiritual and recreational purposes, but recent developments in psychotherapy have highlighted their potential as therapeutic agents. These compounds, which act as potent 5-hydroxytryptamine (5HT) agonists, have been recognized for their ability to enhance neural plasticity through the activation of the serotoninergic and glutamatergic systems....

DOI: 10.1016/j.arr.2024.102211 (opens in new tab) 5-hydroxytryptamine receptors Alzheimer’s disease Brain-derived neurotrophic factor Dementia +7

One- and Two-Photon Excitable Photoswitchable Orthoand Allosteric Ligands of Class A GPCRs

Online Publication Service of Würzburg University (Würzburg University) January 30, 2024 Hubert Georg Lambert Gerwe

Photopharmacology is a vivid field of research that combines the unsurpassed spatiotemporal resolution of light with the principles of pharmacology. By introduction of synthetic chemical photoswitches into the structures of biologically active compounds, researchers can obtain control over biological processes. This is especially useful in the research of G protein-coupled receptors (GPCRs)...

DOI: 10.25972/opus-34870 (opens in new tab) Full text (opens in new tab) G protein-coupled receptor Allosteric regulation Rhodopsin Drug discovery +10

Transient destabilization of whole brain dynamics induced by DMT

bioRxiv January 29, 2024 Juan Ignacio Piccinini, Yonatan Sanz Perl, Carla Pallavicini et al. preprint

Abstract The transition towards the brain state induced by psychedelic drugs is frequently neglected in favor of a static description of their acute effects. We used a time-dependent whole-brain model to reproduce large-scale brain dynamics measured with fMRI from 15 volunteers under 20 mg intravenous N,N-Dimethyltryptamine (DMT), a short-acting psychedelic. To capture its transient effects, we...

On the advances in machine learning and complex network measures to an EEG dataset from DMT experiments

Journal of Physics: Complexity January 22, 2024 Caroline L. Alves, Manuel Ciba, Thaise G. L. de O. Toutain et al. 5 citations

There is a growing interest in the medical use of psychedelic substances, as preliminary studies using them for psychiatric disorders have shown positive results. In particular, one of these substances is N, N-dimethyltryptamine (DMT), an agonist serotonergic psychedelic that can induce profound alterations in the state of consciousness. In this work, we use an exploratory tool to reveal...